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The  mechanisms  involved  in  the  production  of  fever  during  states  of  delayed 
hypersensitivity have only recently begun to be understood. Atkins et al. (1) originally 
showed  that  certain  tissues  from  sensitized rabbits  that  contained  both  phagocytes 
and lymphocytes released the fever-inducing protein endogenous pyrogen (EP)  when 
incubated  with  the  sensitizing  antigen.  Later,  supernates  from  sensitized  rabbit 
lymphocytes incubated with specific antigen were shown to contain a soluble agent or 
lymphokine that  activates macrophages, but  not  polymorphonuclear  (PMN)  leuko- 
cytes to  release  EP  (2).  Similar results have  been  obtained  with  lymphocytes  from 
sensitized  guinea  pigs  incubated  with  homologous  antigen  and  normal  peritoneal 
exudate cells (PEC) but evidence for a soluble agent or lymphokine has been equivocal 
in this model (3). 
Our study shows  that  when  human  lymphocytes are incubated  with  the mitogen 
concanavalin-A (Con-A)  a  nonpyrogenic  lymphokine is released into the supernate. 
This factor activates normal human macrophages, but not PMN leukocytes, to release 
EP  and,  hence,  we  have  named  it  EP-activating  factor  (EPAF).  Because  Con-A 
activates a  larger proportion of lymphocytes than does specific antigen, it should now 
be  possible to  generate  significant  amounts  of human  EPAF,  thus  making  possible 
purification and characterization of this lymphokine. 
Materials  and  Methods 
All materials, glassware, reagents, and solutions were rendered or determined to be pyrogen- 
free by previously described techniques (1). Pyrogen assays were conducted as before in rabbits 
(4). 
Activators.  To  provide  a  positive  control  for  EP  release,  one  aliquot  of cells  in  each 
experiment was incubated with heat-killed staphylococci (in a ratio of 20:1  bacteria:cells) (4). 
Con-A  (lot  58C-7330;  Sigma Chemical Co.,  St.  Louis, Mo.)  was used  exclusively. It  was 
determined to be free of detectable endotoxin contamination (in a concentration of 100/Lg/ml) 
by  the  Limulus amebocyte lysate assay (kindly performed by Dr. John  Ryan, West  Haven 
Veterans Administration Hospital, West Haven, Conn.). 
Incubation of Human Blood Leukocytes with Con-A.  Refrigerated human blood previously passed 
through a cell separator (Haemonetics No. 30; Haemonetics Corp., Natick, Mass.) and depleted 
of granulocytes was obtained from the Red Cross, (Hartford, Conn.). 50 ml of this blood (20 U 
heparin/ml) was added to three volumes of saline and the erythrocytes and remaining PMN 
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leukocytes  removed  by  centrifugation through  Ficoll-Hypaque density  gradients  (4). The 
monocyte-lymphocyte fractions were washed twice in Krebs-Ringer phosphate buffer (KRP) 
and the pellets resuspended in 10-20 ml Eagle's minimum essential medium (Auto Pow; Flow 
Laboratories, Inc., Rockville, Md.)  with  10%  fetal  bovine serum  (Flow  Laboratories,  Inc.) 
(MEM/FBS). Cell counts were determined with a Coulter Particle Counter (model Zr; Coulter 
Electronics Inc. Hialeah, Fla.) and differential smears were made (75-95% lymphocytes and 5- 
25% monocytes). Only preparations with viabilities ~90% by eosin red exclusion were used. 
Aliquots of 1 X 10  s lymphoeytes contained either 4.3 ×  106 ::t: 0.9 ×  106 or 3.3 ×  107 :t:: 0.68 X 
107 monocytes suspended in MEM/FBS (1  ×  107 cells/ml). Like other preparations described 
below, the cells were incubated for 18 h at 37°C in 5% Co2 in 30-ml tissue culture flasks (Falcon 
Labware, Div. Becton, Dickinson, & Co., Oxnard, Calif.) with or without (control) Con-A (10 
p.g/ml).  The cells  were  then centrifuged and the supernates assayed for  EP by intravenous 
injection of 10- to 14-ml doses into rabbits. 
In some experiments, 200 ml heparinized blood (10 U/ml) was drawn by venipuncture  from 
normal volunteers. One-half was subjected to FicolI-Hypaque sedimentation; the other one- 
half to dextran  (100,000-200,000  mol wt;  ICN Nutritional Biochemieals, Cleveland, Ohio) 
sedimentation and hypotonic lysis of erythrocytes. Monocyte-lymphocyte fractions contained 
80-90% lymphocytes and 10-20% monocytes. Leukocyte fractions showed 30-40% lymphocytes, 
55-65% PMN leukocytes, and 5-12% monocytes. Both preparations (in a final concentration of 
I ×  l07 cells/ml) were incubated for  18 h in MEM/FBS with and without Con-A (10~g/ml). 
The supernates were removed and assayed for EP in dosages  equivalent to ~5 ×  10  PMN, 
4 ×  10~monocytes, and 2 X  107 iymphocytes (derived from dextran-sedimented cells) or 4 × 
106 monocytes and 2 ×  107 lymphocytes alone (derived from FicolI-Hypaque centrifugation). 
The  cells  were  then  resuspended  in  MEM/FBS  and  reincubated for  an  additional  18  h. 
Supernates from these second harvests were tested for EP in the same dosages  used initially. 
Production of EPAF.  10 ml heparinized blood (50 U/ml) that had been passed through a cell 
separator (see above) was  diluted with  10 ml Plasmagel (Associated  Biomedic Systems, Inc., 
Buffalo, N. Y.) and then allowed to settle at 37°C for 20 min. The plasma portion was decanted, 
diluted to 40 ml with MEM/FBS, and 1 g of carbonyl iron powder (GAF Corp., New York) 
was added. The suspension was rotated at 37°C for 25 min and the iron and iron-containing 
macrophages  drawn  down  with  a  magnet  until  the  plasma  portion  was  clear  (5). The 
lymphocytes and the few residual monocytes remaining after centrifugation of the supernates 
through Ficoll-Hypaque gradients were washed three times in KRP and resuspended in 10 ml 
MEM/FBS. The cells (96-99%  lymphocytes and 1-4% monocytes) were suspended to a  final 
concentration of 1 x  10  v cells/ml in MEM/FBS and incubated for  18 h  in the presence or 
absence (control)  of Con-A (10 #g/ml). The cells were then centrifuged and the supernates 
dialyzed against distilled water for 48 h and lyophilized to a  powder. Material derived from 
1 X l0  s lymphocytes was dissolved  in individual doses of 2 ml MEM/FBS and assayed for EP 
directly (by intravenous injection) or for EP-inducing activity (see below). 
Assay for EPAF.  200-300 ml heparinized blood (10 U/ml) were  drawn from each of two 
normal adult volunteers by venipuncture. Mononuclear  cells (8-15% monocytes) were separated 
by Ficoll-Hypaque density centri,fu~ation and suspended in MEM/FBS (1 ×  107-2 X 107 cells/ 
ml).  Aliquots containing 2  X  10  monocytes were  layered  on  30-ml  tissue  culture  flasks, 
incubated for  2  h,  and the  adherent  cells  then washed  three  times with  MEM/FBS.  The 
number of monocytes that adhered to the flask (one-third to one-fifth the initially layered cells) 
was determined by subtracting the number of monocytes (2-15% of the nonadherent popula- 
tion) from the total number of monocytes added to each flask. 
After removal of the nonadherent cells, lyophilized preparations of EPAF or control material 
were reconstituted in 4 ml MEM/FBS (as two doses derived from 2 ×  l0  s lymphocytes) and 
added to the adherent cells in the flasks. Con-A was added to the control material in the same 
concentration (10 #g/ml) as in the experimental sample of lymphocytes incubated with Con-A. 
The adhered macrophages were then incubated for 18 h. After this time, the supernates (in two 
doses, each derived from ~ 1 x  107 macrophages) were assayed for EP. The adhered cells were 
then washed  once and reincubated in 4  ml  fresh  MEM/FBS  for  additional  18  h  and  the 
supernates assayed as before for EP. 
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pended in MEM/FBS (1 X  10  7 cells/ml; containing 25-35% lymphocytes, 55-65% granulocytes, 
and 5-10% monocytes). Aliquots containing 4 ×  10  7 PMN leukocytes were layered on 30-ml 
tissue culture flasks and incubated for 2 h. After this period,  the adherent  cells were washed 
three  times with  MEM/FBS. The number of adhered  granulocytes  was determined,  as with 
monocytes, by subtracting the number of granulocytes (10-25% of the nonadherent population) 
from the number of granulocytes initially layered on the tissue culture flasks. After adherence, 
reconstituted  preparations  containing EPAF or control  material  (with  added  Con-A)  were 
added  to  each  flask, as  in  the  preceding  experiments,  and  the  flasks incubated  for  18  h. 
Supernates  (in two doses, each derived from 2 ×  10  7 PMN leukocytes) were then assayed for 
EP. The adhered  cells were reincubated  for an additional  18 h in fresh MEM/FBS as before, 
and the supernates  assayed (as a second harvest) for EP. 
Results 
Release of EP by Human Monocytes Incubated with Lymphocytes and Con-A.  To determine 
whether human  monocytes could release  EP when cocuhured with  lymphocytes in 
the presence of Con-A, mononuctear cells derived from granulocyte-depleted banked 
blood were suspended in MEM/FBS and incubated  18 h  with and without Con-A. 
(Materials  and Methods). The supernates were then assayed for EP. As can be seen 
from Fig. 1, doses of ~3 ×  10  7 monocytes, when cocuhivated with Con-A and  1 ×  l0  s 
lymphocytes, released substantial amounts of EP.  Little if any EP was released with 
lower numbers of monocytes (~4.5  ×  106), although the same number of monocytes 
released significant amounts of EP in response to phagocytosis of heat-killed Staphy- 
lococcus albus. 
Release of  a Soluble EPAF by Lymphocytes Incubated with Con-A.  To determine if human 
lymphocytes secrete a  lymphokine (EPAF)  that  activates phagocytes to release  EP, 
lymphocytes isolated from banked blood were incubated for  18 h  with and without 
Con-A.  Supernates  (dialyzed,  lyophilized,  and  reconstituted  in  a  small  volume of 
MEM/FBS)  were added  to tissue  culture  flasks  containing freshly adhered  macro- 
phages (Materials and Methods). After 18 h incubation, the supernates were removed 
for EP assay and the macrophages reincubated  18 h in fresh MEM/FBS for a second 
harvest.  As shown in  Fig.  2A, material  derived from  1 ×  10  s lymphocytes (though 
containing no detectable EP itself)  activated  1 ×  107 macrophages to release signifi- 
cant  amounts  of  EP  during  the  first  and  second  incubations.  Supernates  from 
lymphoeytes incubated without mitogen, to which Con-A was added after separation 
of cells,  did not activate adherent macrophages to release EP, indicating that Con-A 
does not directly activate these cells  to produce EP. 
The target cell from human EPAF appears to be the macrophage rather than the 
PMN because EPAF derived from the same number (1  ×  10  s)  lymphocytes failed to 
activate 2 ×  107 adherent PMN leukocytes (containing a small contaminating number 
of monocytes) to release EP (Fig. 2 B). These cell populations were, however, activated 
to produce EP by S.  albus. In four additional experiments  (data not shown), similar 
amounts of pyrogen were released after phagocytosis of S. albus, both in the presence 
and absence of mitogen (0.78  ±  0.26°C and 0.63 ±  0.18°C with and without Con-A 
[10/1g/roll, respectively). Con-A, therefore, in concentrations present in preparations 
containing EPAF, does not appear to alter the ability of this population of cells to 
generate EP when incubated with another pyrogenic stimulus. 
Inhibition of EP Release by Monocytes Cocultured with Lymphocytes in the Presence of Con-A: 
Role of the PMN Leukocyte.  To determine  if PMN  leukocytes can  release  EP when 
cocultured  directly  with  lymphocytes  in  the  presence  of Con-A,  leukocytes  were 1814  BERNHEIM  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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F[G.  1.  Mean  febrile responses (_ SEM)  to EP released by mixtures of human lymphocytes and 
monocytes (from banked blood) incubated 18 h either alone or with Con-A or staphylococci (Staph) 
(see  text). Detectable amounts of EP were released only with the higher dose of monocytes when 
Con-A was used as the stimulus. Each dose was derived from  1 ×  10  ~ lymphocytes and either 4.5 
--.  1.3 X  10  ~ monocytes or 30 4-  10.2 ×  10  ~ monocytes, n, number of recipient rabbits. 
Fie.  2.  (A)  Mean  febrile  responses  (::1: SEM)  to  EP  released  by  adherent  human  monocytes 
incubated for two successive 18-h periods (1 ° and 2 ° harvest) with a lymphokine (LK) produced by 
prior  18-h  incubation of human  lymphocytes with  and  without  (LK  control)  con-A  (see  text). 
Febrile  responses  to  the  LK  alone  and  to  adherent  human  granulocytes  (B)  under  the  same 
conditions  are  shown  for  comparison.  EP  production  by  both  populations  of  adherent  cells 
(monocytes and granulocytes) when incubated with heat-killed staphylococci (Staph) is also shown. 
In (A), each dose was derived from 9.7 X  l0  ~i 4- 2.1  X  10  ~ adherent monocytes; in B, from  1.8 ×  10  ~ 
+  0.38  ×  10  ~ granulocytes with 2.2  X  10  ~ +  0.54 x  10  ~ monocytes. The LK was derived from  -1 
×  l0  s lymphocytes incubated with Con-A. Con-A was added to the LK control before incubation 
with the adherent cells in both (A) and (B). 
FtG.  3.  Mean febrile responses (+ SEM)  to EP produced by leukocytes from  fresh human blood 
incubated for  two successive 18-h  periods  (1 °  and  2 °  harvest) with and  without Con-A or with 
staphylococci (Stash). In (A), each dose wasflerived from 5.2 x  107 +  0.15 X  10 7 granulocytes, 0.43 
X  10'  -I- 0.14 X  10  monocytes, and  1.9 X  10'  +_ 0.3 X  10'  lymphocytes. In B, each dose was derived 
from 0.36 X  107 +  0.08 X  107 monocytes and 2.3  X  107 4- 0.2 X  l07 lymphocytes only. 
isolated from fresh venous blood by dextran sedimentation (Materials and Methods). 
Aliquots  of cells  (~5  ×  107  PMN  leukocytes,  2  X  107  lymphocytes, and  4  X  10  6 
monocytes) were then suspended  in  MEM/FBS  (1  X  107 cells/ml)  with or without 
10 ~g/ml of Con-A, and incubated for 18 h. The supernates were then assayed for EP. 
Under these conditions, PMN leukocytes released  little or no EP  (Fig.  3A).  In fact, 
the  granulocytes  appeared  to  inhibit  the  release  of EP  by  the  same  number  of 
monocytes, derived from the same source and cocultivated alone with  lymphocytes 
and Con-A (Fig.  3 B). 
Discussion 
Although  Con-A  is  known  to activate  unsensitized  lymphocytes  to secrete  several 
lymphokines  (6),  its  role  in  the  pathogenesis  of  fever  has  not  been  previously 
demonstrated  with  material  known  to  be  free  of contaminating  endotoxins  (7).  We 
believe that our experiments  are the first to show that human lymphocytes incubated 
with  Con-A  release a  soluble  factor that  activates  human  phagocytes  to release  EP. 1 
1 Dinarello et  al.  (8)  have recently reported that supernates from human mixed lymphocyte reactions 
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We have called this factor EPAF. The target cell appears to be the macrophage rather 
than the granulocyte. This limitation of action to a particular cell type is not unique 
among iymphokines, as maerophage inhibitory factor (MIF) and leukocyte inhibitory 
factor have as their target cells the macrophage and PMN leukocyte, respectively (9, 
10). Recent work suggests that pure populations of PMN leukocytes produce little if 
any EP when  incubated with a  standard  pyrogenic stimulus such as staphylococci 
(11). In the ease of this EP-producing lymphokine, PMN leukocytes actually appeared 
to inhibit the release of EP from cocultured macrophages incubated with lymphocytes 
and  Con-A.  The  nature  of this  inhibitory  action  is  unknown.  Possibilities  to  be 
investigated include competition for EPAF by granulocytes and macrophages (which 
were present in a ratio of 10:1, respectively) or release of a substance by granulocytes 
that inhibits either the production of EPAF by lymphocytes or its action on its target 
cell, the macrophage. 
The type(s) of lymphocyte(s) (T and/or B) which secretes human EPAF is unknown, 
but a  considerable body of evidence indicates that  Con-A differentially activates T 
cells  (6).  Recent work in our laboratory has shown  that  populations of specifically 
sensitized guinea pig lymphocytes depleted of B cells, when incubated with antigen, 
will activate peritoneal macrophages to produce EP in vitro (3). However, because of 
the necessity of obtaining relatively large numbers of cells under pyrogen-free condi- 
tions for this  assay,  we have not yet obtained a  sufficiently purified population of 
B cells to determine if these lymphocytes can also activate phagocytes to release EP. 
Because Rocklin et al.  (12)  have shown that both human T  and B cells are capable 
of producing MIF,  there is a  clear possibility that  both types of lymphocytes may 
similarly release human EPAF. 
EPAF appears  to be the first human  lymphokine to be clearly associated with  a 
known pathologic phenomenon, fever. Because fever is known to decrease the mor- 
tality rate of infected lizards (13) and, possibly, of infected mammals as well (14), this 
factor  may  be  important  in  the  host's  defense  against  microbial  pathogens.  Its 
characterization, therefore, may have great clinical significance. Because as little as 
2  ×  10  7 fresh  lymphocytes produce  a  detectable  dose  of EPAF,  in  contrast  to  a 
minimum dose of ~ 1 ×  l0  s lymphocytes from banked blood, it should be possible to 
generate large amounts of this lymphokine. Partial purification and characterization 
of this important activator of monocytes now appear to be feasible. 
Summary 
Evidence is presented that the mitogen concanavalin A stimulates human lympho- 
cytes  to  produce  a  nonpyrogenic  lymphokine  (LK)  that  is  capable  of activating 
human monocytes but not granulocytes to produce endogenous pyrogen (EP) in vitro. 
The  potency  of this  preparation  should  facilitate  further  studies  to  purify  and 
characterize this agent and determine its relation to other known LK. 
It seems likely that this factor, which we have called EP-activating factor (EPAF), 
plays a significant role in the development of fever in states of delayed hypersensitivity 
in man. 
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